Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors
Open accessThe DOI matches its Crossref record; 21 of the 23 references it cites were found in a registry or an index.
Abstract
Objectives A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the patients with chronic heart failure (HF) not receiving angiotensin-converting enzyme (ACE) inhibitors.Background The ACE inhibitors reduce mortality and morbidity in patients with HF. Nonetheless, nearly 20% of potentially eligible patients may not be prescribed ACE inhibitors.Results Val-HeFT was an international, randomized, double-blinded trial that compared valsartan with placebo when added to the prescribed treatment of patients with HF. The two primary end points of the study were all-cause mortality and the composite of all-cause mortality and morbidity (sudden death with resuscitation, hospital admission for HF, or administration of intravenous inotropic or vasodilator drugs for >or=4 h without hospital admission). Of the 5,010 patients enrolled in the trial, 366 (7.3%) were not treated with ACE inhibitors at baseline. The effects of valsartan on the primary and secondary end points of the study were assessed in this subgroup of patients.Results Both all-cause mortality and combined mortality and morbidity for patients not treated with ACE inhibitors were significantly reduced in the valsartan treatment group compared with the placebo group (17.3% vs. 27.1%, p = 0.017 and 24.9% vs. 42.5%, p < 0.001, respectively). Consistent with the data on clinical events, patients randomized to valsartan showed improvements in physiologic variables, such as ejection fraction, left ventricular internal diameter in diastole, and plasma neurohormone levels. Permanent discontinuation of study treatment because of adverse experiences was comparable between the two groups.Conclusions Val-HeFT has provided the first placebo-controlled outcome data demonstrating a favorable effect of an angiotensin receptor blocker on mortality and morbidity in patients with HF not treated with ACE inhibitors. Based on these results, valsartan appears to be an effective therapy in ACE inhibitor-intolerant patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An RCT in self-identified Black patients with HFrEF showed that adding the combination of hydralazine and isosorbide dinitrate to conventional therapy (ACE-I, beta-blocker, MRA) reduced mortality and HF hospitalization in patients in NYHA class III-IV.517 The beneficial effects were consistent in patients with or without diabetes.518”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [517]
In the citing paper
“Also, in the Val-HeFT, valsartan treatment led to a significant relative risk reduction in the co-primary composite endpoint (death or HF morbidity-mainly HF hospitalization) regardless of T2DM.145”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [145]
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029 · cited 1×
“In this population of patients at high risk of clinical events, the favorable effect of valsartan appears to be similar to that obtained with ACE inhibitors, when these drugs were compared with placebo (15,16).”
ResultEffects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationPitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Garg, R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520420066040 · Cited by 1,771 · cited 1×
“Angiotensin-converting enzyme (ACE) inhibitors reduce the mortality and morbidity of patients with chronic heart failure (HF) (1).”
BackgroundPitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665 · cited 1×
“In any case, as suggested by previous contradictory conclusions derived from underpowered studies (17,18), these results should be interpreted with caution and need to be confirmed in larger randomized trials, and in this respect, the final results of the Candesartan in Heart failure— Assessment of Reduction in Mortal…”
ResultLiu, Y. H., Yang, X. P., Sharov, V. G., Nass, O., Sabbah, H. N., Peterson, E., & Carretero, O. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119360 · Cited by 603
Hornig, B., Kohler, C., & Drexler, H. (1997) · Circulation · doi:10.1161/01.cir.95.5.1115 · Cited by 333 · cited 2×
“The mechanisms of the beneficial effect of ACE inhibitors are not fully established, but it is likely that inhibition of angiotensin II production is at least partially responsible (2,3).”
BackgroundSwedberg, K., Pfeffer, M., Granger, C., Held, P., Mcmurray, J., Ohlin, G., Olofsson, B., Östergren, J., & Yusuf, S. (1999) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(99)90013-1 · Cited by 294 · cited 1×
“In any case, as suggested by previous contradictory conclusions derived from underpowered studies (17,18), these results should be interpreted with caution and need to be confirmed in larger randomized trials, and in this respect, the final results of the Candesartan in Heart failure— Assessment of Reduction in Mortal…”
Result
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
“contraindicated, to reduce morbidity and mortality (108,345,415,450).”
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Metadata
- Authors
- Maggioni, A. P., Anand, I., Gottlieb, S. O., Latini, R., Tognoni, G., & Cohn, J. N.
- Affiliations
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Minneapolis VA Medical Center (US)
- Mario Negri Institute for Pharmacological Research (IT)
- University of Minnesota (US)
- Corresponding author
- Maggioni, Aldo P
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2002-10
- Volume
- 40
- Issue
- 8
- Pages
- 1414-1421
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2110831147
- Cited by
- 356
- References
- 23
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 7 · 2023: 4 · 2022: 7 · 2021: 14 · 2020: 10 · 2019: 10 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 14
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3978 d)
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- valsartan, chronic heart failure, angiotensin receptor blockers, ACE inhibitors, ACE inhibitor intolerance, Val-HeFT trial, all-cause mortality, heart failure morbidity, ejection fraction, neurohormones, subgroup analysis
- MeSH terms
- Valsartan, Aged, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Female, Heart Failure, Humans, Male, Middle Aged, Quality of Life, Tetrazoles, Valine, Randomized Controlled Trials as Topic, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. https://app.cochat.ai/papers/10.1016/s0735-1097(02)02304-5
- The paper
- Maggioni, A. P., Anand, I., Gottlieb, S. O., Latini, R., Tognoni, G., & Cohn, J. N. (2002). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology. https://doi.org/10.1016/s0735-1097(02)02304-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.